AVCN TOR Week ended 24 Jul 2026

Weekly Investor Report

Avicanna Inc. · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 0.14 CAD
8.0% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -14.4% below the Trend Line and sits at 19.7% of its 52-week range. The latest completed week returned 8.0%, after a 12.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.

Setup score 26 out of 100
Latest Close 0.14 CAD 24 Jul 2026
1W Return 8.0% latest completed week
4W Return 12.5% short-term follow-through
12W Return -6.9% quarterly tape
Trend Breadth 7.7% 4 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
  • Latest weekly return ranks in the strongest part of its sector group.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 42.69% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.0% Latest completed week; four-week move 12.5%. Indicator stack 4/71 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.69% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 13 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -14.4% below the Trend Line and sits at 19.7% of its 52-week range. The latest completed week returned 8.0%, after a 12.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0112-week average 0.00

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 12.5% over four weeks, -6.9% over 12 weeks, and -52.6% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W8.0%
4W12.5%
12W-6.9%
26W-38.6%
52W-52.6%
Active trend streak0 weeks
Active weeks in one year4
Trend breadth7.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.41Latest activity-pressure read.
Pressure change175.9%Four-week change in activity pressure.
Leadership-40.14Latest relative-leadership reading.
RS change19.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 76% Model confidence 73%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength71/100Blend of value, momentum, and quality. Underlying universe rank 30; rank 1 is best.
Value59/100Relative valuation strength. Underlying universe rank 42; rank 1 is best.
Quality61/100Profitability and accounting quality. Underlying universe rank 40; rank 1 is best.
Momentum61/100Medium-term price momentum. Underlying universe rank 40; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.7x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-8.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
53.2%
Gross profit retained from each unit of revenue.
Operating margin
-12.3%
Operating profit retained from revenue.
Free-cash-flow margin
-8.7%
Free cash flow generated from revenue.
Return on invested capital
-67.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
0.1%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-15.0%
Net share repurchases relative to market value.
Shareholder yield
-15.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 13 relevant articles.

0 positive · 13 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-54.7%Distance below the 52-week high.
13-week volatility5.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher7 of 2612 weeks finished lower.
Best week+8.7%Week of 12 Jun.
Worst week-12.2%Week of 6 Feb.
Latest week+8.0%Week of 24 Jul.

Shape of recent returns

Strong gains5
Modest gains2
Flat weeks7
Modest losses2
Sharp losses10
Recent vol5.7%13-week weekly-return volatility.
Base vol4.4%52-week weekly-return volatility.
Up/down split13/23Count of positive and negative weeks in the 52-week window.
Average skew4.3% / -5.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis14/100

Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.

Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 42.69%

Next-week expectancy is negative with a 42.69% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors62/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 94 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 13 relevant articles.

Why Avicanna Inc stock is rising today Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.14 CAD8.0%0.16 CAD0.30 CAD0.41-40.14251.3KOff
17 Jul 20260.12 CAD4.2%0.16 CAD0.30 CAD0.30-45.49285.8KOff
10 Jul 20260.12 CAD0.0%0.16 CAD0.30 CAD0.17-48.581.5MOff
3 Jul 20260.12 CAD0.0%0.17 CAD0.30 CAD-0.17-49.31875.8KOff
26 Jun 20260.12 CAD-7.7%0.17 CAD0.30 CAD-0.54-49.791.2MOff
19 Jun 20260.13 CAD4.0%0.18 CAD0.30 CAD-0.67-46.5981.4KOff
12 Jun 20260.12 CAD8.7%0.18 CAD0.30 CAD-0.64-49.50527.8KOff
5 Jun 20260.12 CAD-8.0%0.18 CAD0.31 CAD-0.45-53.52185.5KOff
29 May 20260.12 CAD-3.8%0.19 CAD0.31 CAD-0.33-50.951.1MOff
22 May 20260.13 CAD-7.1%0.19 CAD0.31 CAD-0.55-49.44917.2KOff
15 May 20260.14 CAD3.7%0.20 CAD0.31 CAD-0.72-45.43857.2KOff
8 May 20260.14 CAD-6.9%0.20 CAD0.31 CAD-0.97-48.65768.3KOff
1 May 20260.14 CAD-3.3%0.21 CAD0.31 CAD-1.04-45.35576.6KOff
24 Apr 20260.15 CAD0.0%0.21 CAD0.32 CAD-1.06-44.181.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.